Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment
- 주제(키워드) Aptamer , Drug delivery , Oligobody , Pancreatic ductal adenocarcinoma , Targeted therapy
- 등재 SCIE, SCOPUS
- OA유형 All Open Access; Hybrid Gold Open Access
- 발행기관 Elsevier B.V.
- 발행년도 2023
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000211571
- 본문언어 영어
- Published As https://doi.org/10.1016/j.jconrel.2023.03.048
- PubMed 37001565
초록/요약
Owing to a lack of reliable markers and therapeutic targets, pancreatic ductal adenocarcinoma (PDAC) remains the most lethal malignant tumor despite numerous therapeutic advances. In this study, we utilized cell-SELEX to isolate a DNA aptamer recognizing the natural conformation of the target on the cell surface. PAp7T8, an aptamer optimized by size and chemical modification, exhibited specific targeting to pancreatic cancer cells and orthotopic xenograft pancreatic tumors. To confer therapeutic functions to the aptamer, we adopted a drug-conjugated oligobody (DOligobody) strategy. Monomethyl auristatin E was used as a cytotoxic drug, digoxigenin acted as a hapten, and the humanized anti-digoxigenin antibody served as a universal carrier of the aptamer. The resulting PAp7T8-DOligobody showed extended in vivo half-life and markedly inhibited tumor growth in an orthotopic pancreatic cancer xenograft model without causing significant toxicity. Therefore, PAp7T8-DOligobody represents a promising novel therapeutic delivery platform for PDAC. © 2023 The Authors
more